FDA Drug recall D-0926-2017
Gaviscon (Alumina & Magnesium Trisilicate) Regular Strength Original Flavor Chewable Tablets, 80 mg & 14.2 mg, 100-count bottles, Distribut…
- FDA Drug
- Class III
- terminated
- Published 2017-07-05
On 2017-07-05 the FDA classified a Class III recall of Gaviscon (Alumina & Magnesium Trisilicate) Regular Strength Original Flavor Chewable Tablets, 80 mg & 14.2 mg, 100-count bottles, Distribut… by Sanofi Aventis U S, citing superpotent Drug: high out-of-specification result for magnesium.
Read the official FDA Drug notice
| Agency | FDA Drug |
|---|---|
| Recall number | D-0926-2017 |
| Classification | Class III |
| Status | terminated |
| Initiated | 2017-06-12 |
| Published | 2017-07-05 |
| Last updated | 2026-09-13 11:51 UTC |
| Company | Sanofi Aventis U S |
| Distribution | US |
Product
Gaviscon (Alumina & Magnesium Trisilicate) Regular Strength Original Flavor Chewable Tablets, 80 mg & 14.2 mg, 100-count bottles, Distributed by: GlaxoSmithKline Consumer Healthcare, L.P., Moon Twp, PA 15108, UPC 3 0088-1175-47 8.
Reason
Superpotent Drug: high out-of-specification result for magnesium.
Identifiers
| upc | 300881175478 |
|---|---|
| code_info | Lot #: 5J69A, Exp 02/19; 6GF2A, 6GF3A, Exp 08/19 |
Status history
No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:51 UTC. Current status: terminated.
Source
Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0926-2017%22
RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.